New cancer drug OCT-598 enters first human tests for advanced tumors
NCT ID NCT07358806
First seen Jan 24, 2026 · Last updated May 21, 2026 · Updated 20 times
Summary
This early-stage study tests a new drug called OCT-598 in about 51 adults with advanced solid tumors (breast, lung, prostate, head/neck, or stomach cancer). The main goals are to check safety, find the best dose, and see how the drug works alone or with standard treatments. Participants must have tried other options and have adequate organ function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
NOT_YET_RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center
RECRUITINGGoyang-si, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Seoul National University Bundang Hospital (SNUBH)
RECRUITINGSeongnam-si, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.